Preview

Атеротромбоз

Расширенный поиск

АНТИТРОМБОТИЧЕСКИЕ ПРЕПАРАТЫ В ПРОФИЛАКТИКЕ ТРОМБОТИЧЕСКИХ И ТРОМБОЭМБОЛИЧЕСКИХ ОСЛОЖНЕНИЙ ПОСЛЕ ОСТРОГО КОРОНАРНОГО СИНДРОМА

https://doi.org/10.21518/2307-1109-2013-1-82-104

Полный текст:

Аннотация

.

Об авторе

И. С. Явелов
Лаборатория клинической кардиологии ФГБУН «НИИ физико-химической медицины» ФМБА России, г. Москва
Россия


Список литературы

1. Hasdai D., Behar S., Wallentin L., et al. A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin; the Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS) // Eur. Heart J. 2002. №23. Р. 1190−1201.

2. Goldberg R.J., Currie K., White K., et al. Six-month outcomes in a multinational registry of patients hospitalized with an acute coronary syndrome (the Global Registry of Acute Coronary Events [GRACE]) // Am. J. Cardiol. 2004. №93. Р. 288−293.

3. Yan A.T., Tan M., Fitchett D., et al. One-year outcome of patients after acute coronary syndromes (from the Canadian Acute Coronary Syndromes Registry) // Am. J. Cardiol. 2004. №94. Р. 25−29.

4. Fox Keith. A.A., Carruthers K.F., Dunbar D.R., et al. Underestimated and under-recognized: the late consequences of acute coronary syndrome (GRACE UK–Belgian Study) // Eur. Heart J. 2010. doi:10.1093/eurheartj/ehq326.

5. Chan M.Y., Mahaffey K.W., Sun L.J., et al. Prevalence, Predictors, and Impact of Conservative Medical Management for Patients With Non–STSegment Elevation Acute Coronary Syndromes Who Have Angiographically Documented Significant Coronary Disease // JACC Cardiovasc. Int. 2008. №1. Р. 369−378.

6. Chan M.Y., Sun J.L., Newby L.K., et al. Long- Term Mortality of Patients Undergoing Cardiac Catheterization for ST-Elevation and Non-STElevation Myocardial Infarction // Circulation. 2009. №119. Р. 3110−3117.

7. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction. A Report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines // JACC. 2013. 61. doi:10.1016/j. jacc.2012.11.019.

8. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC) // Eur. Heart J. 2012. doi:10.1093/eurheartj/ehs215.

9. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association // Eur. Heart J. 2012. doi:10.1093/eurheartj/ehs253.

10. Vandvik P.O., Lincoff A. M., Gore J.M., et al. Primary and Secondary Prevention of Cardiovascular Disease. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines // Chest. 2012. №141 (Suppl.) Р. e637S–e668S.

11. Antithrombotic Trialists’ (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials // Lancet. 2009. №373. Р. 1849−1860.

12. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) // Lancet. 1996. №348. Р. 1329–3139.

13. Sоrensen R., Hansen M.L., Abildstrom S.Z., et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data // Lancet. 2009. №374. Р. 1967−1974.

14. Lanas A., Garcia-Rodriguez L.A., Arroyo M.T., et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclooxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations // Gut. 2006. №55. Р. 1731−1738.

15. Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without SТ-segment elevation // N. Engl. J. Med. 2001. №345. Р. 494−502.

16. Fox K.A.A., Mehta S.R., Peters R., et al. Benefits and Risks of the Combination of Clopidogrel and Aspirin in Patients Undergoing Surgical Revascularization for Non–ST-Elevation Acute Coronary Syndrome The Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial // Circulation. 2004. №110. Р. 1202−1208.

17. Mehta S.R., Yusuf S., Peters R.J.G., et al., for the Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study // Lancet. 2001. №358. Р. 527−533.

18. Sabatine M.S., Cannon C.P., Gibson C.M., et al. Addition of Clopidogrel to Aspirin and Fibrinolytic Therapy for Myocardial Infarction with ST-Segment Elevation // N. Engl. J. Med. 2005. №352. Р. 1179−1189.

19. COMMIT (Clopidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomized placebo-controlled Trial // Lancet. 2005. №366. Р. 1607–1621.

20. Budaj A., Yusuf S., Mehta S.R., et al., for the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Trial Investigators. Benefit of Clopidogrel in Patients With Acute Coronary Syndromes Without ST-Segment Elevation in Various Risk Groups // Circulation. 2002. №106. Р. 1622−1626.

21. Bhatt D.L., Fox K.A.A., Hacke W., et al., for the CHARISMA Investigators. Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events // N. Engl. J. Med. 2006. №354. Р. 1706−1717.

22. The ACTIVE Investigators. Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation // N. Engl. J. Med. 2009. doi: 10.1056/ NEJMoa0901301.

23. Ben-Dor I., Torguson R., Scheinowitz M., et al. Incidence, correlates, and clinical impact of nuisance bleeding after antiplatelet therapy for patients with drug-eluting stents // Am. Heart. J. 2010. №159. Р. 871−875.

24. Roy P., Bonello L., Torguson R., et al. Impact of «nuisance» bleeding on clopidogrel compliance in patients undergoing intracoronary drug eluting stent implantation // Am. J. Cardiol. 2008. №102. Р. 1614−1617.

25. Amin A.P., Bachuwar A., Reid K.J., et al. Nuisance Bleeding With Prolonged Dual Antiplatelet Therapy After Acute Myocardial Infarction and its Impact on Health Status // JACC. 2013. doi: 10.1016/j. jacc.2013.02.044.

26. Bhatt D.L., Cryer B.L., Contant C.F., et al., for the COGENT Investigators. Clopidogrel with or without Omeprazole in Coronary Artery Disease // N. Engl. J. Med. 2010. 10.1056/NEJMoa1007964.

27. Wallentin L., Becker R.C., Budaj A., et al., for the PLATO Investigators. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes // N. Engl. J. Med. 2009. №361. Р. 1045−1057.

28. Kearon C., Akl E.A., Comerota A.J., et al. Antithrombotic Therapy for VTE Disease. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence- Based Clinical Practice Guidelines // Chest. 2012. №141 (Suppl.). Р. e419S–e494S.

29. Guidelines on the management of valvular heart disease (version 2012). The Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) // Eur. Heart J. 2012. doi:10.1093/ eurheartj/ehs109.

30. Management of Patients With Atrial Fibrillation (Compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS Recommendations). A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines // Circulation. 2013. №127. URL: http:// circ.ahajournals.org/content/early/2013/04/01/ CIR.0b013e318290826d.citation.

31. 2008 Focused Update Incorporated Into the ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease) // JACC. 2008. №52. Р. e1−142.

32. Guidelines on the diagnosis and management of acute pulmonary embolism. The Task Force for the Diagnosis and Management of Acute Pulmo nary Embolism of the European Society of Cardiology // Eur. Heart J. 2008. №29. Р. 2276−2315.

33. Anand S.S., Yusuf S. Oral Anticoagulants Therapy in Patients With Coronary Artery disease. A Metaanalysis // JAMA. 1999. №282. Р. 2058−2067.

34. Rothberg M.B., Celestin C., Fiore L.D., et al. Warfarin plus Aspirin after Myocardial Infarction or the Acute Coronary Syndrome: Meta-Analysis with Estimates of Risk and Benefit // Ann. Intern. Med. 2005. №143. Р. 241−250.

35. Andreotti F., Testa L., Giuseppe G.L., et al. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25 307 patients // Eur. Heart J. 2006. №27. Р. 519−526.

36. van Es R.F., Jonker J.J.C., Verheugt F.W.A., et al., for the Secondary Prevention of Events in Coronary Thrombosis-2 (ASPECT-2) Research Group. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial // Lancet. 2002. №360. Р. 109–113.

37. Hurlen M., Abdelnoor M., Smith P., et al. Warfarin, aspirin, or both after myocardial infarction // N. Engl. J. Med. 2002. №347. Р. 969−974.

38. Coumadin Aspirin Reinfarction Study (CARS). Investigators Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction // Lancet. 1997. №350. Р. 389–396.

39. Hansen M.L., Sоrensen R., Clausen M.T., et al. Risk of Bleeding With Single, Dual, or Triple Therapy With Warfarin, Aspirin, and Clopidogrel in Patients With Atrial Fibrillation // Arch. Intern. Med. 2010. №170. Р. 1433−1441.

40. Testa L., Zoccai G.B., Porto I., et al. Adjusted Indirect Meta-Analysis of Aspirin Plus Warfarin at International Normalized Ratios 2 to 3 Versus Aspirin Plus Clopidogrel After Acute Coronary Syndromes // Am. J. Cardiol. 2007. №99. Р. 1637−1642.

41. The ACTIVE Writing Group on behalf of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial // Lancet. 2006. №367. Р. 1903−1912.

42. Nikolsky E., Mehran R., Dangas G.D., et al. After Primary Percutaneous Coronary Intervention for STElevation Myocardial Infarction (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction [HORIZONS-AMI] Trial) // Am. J. Cardiol. 2012. №109. Р. 831−838.

43. Schomig A., Sarafoff N., Seyfarth M. Triple antithrombotic management after stent implantation: when and how? // Heart. 2009. №95. Р. 1280−1285.

44. Lip G.Y.H., Huber K., Andreotti F., et al. Management of Antithrombotic Therapy in Atrial Fibrillation Patients Presenting with Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention/ Stenting. A Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association [EHRA] and the European Association of Percutaneous Cardiovascular Interventions [EAPCI] // Thromb. Haemost. 2010. №103. Р. 13−28.

45. Dewilde W.J.M., Oirbans T., Verheugt F.W.A., et al., for the WOEST study investigators Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial // Lancet. 2013. URL:http://dx.doi. org/10.1016/S0140-6736(12)62177-1.

46. Mega J.L., Braunwald E., Wiviott S.D., et al., for the ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in Patients with a Recent Acute Coronary Syndrome // N. Engl. J. Med. 2011. doi: 10.1056/ NEJMoa1112277.

47. Cassese S., Byrne R.A., Tada T., et al. Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drugeluting stent era: a meta-analysis of randomized trials // Eur. Heart J. 2012. №33. Р. 3078–3087.

48. Kim B.-K., Hong M.-K., Shin D.-H., for the RESET Investigators. New Strategy for Discontinuation of Dual Antiplatelet Therapy. The RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation) // JACC. 2012. №60. Р. 1340–1348.

49. URL:http://www.clinicaltrials.gov/ct2/show/N CT00776633?term=ISAR&recr=Open&rank=9.

50. Sarafoff N., Martischnig A., Wealer J., et al. Triple therapy with aspirin, prasugrel and vitamin K antagonists in patients with drug eluting stent implantation and an indication for oral anticoagulation // JACC. 2013. doi: 10.1016/j. jacc.2013.02.036.

51. White H.D., Gruber M., Feyzi J., et al. Comparison of Outcomes Among Patients Randomized to Warfarin Therapy According to Anticoagulant Control. Results From SPORTIF III and V // Arch. Intern. Med. 2007. №167. Р. 239−245.

52. Ageno W., Gallus A.S., Wittkowsky A., et al. Oral Anticoagulant Therapy. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines // Chest. 2012. №141 (Suppl.). Р. e44S–e88S.

53. Heneghan C., Alonso-Coello P., Garcia-Alamino J.M., et al. Self-monitoring of oral anticoagulation: a systematic review and meta-analysis // Lancet. 2006. №367. Р. 404–411.

54. Linkins L.A., Choi P.T., Douketis J.D. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis // Ann. Intern. Med. 2003. №139. Р. 893−900.

55. Hylek E.M., Evans-Molina C., Shea C., et al. Major Hemorrhage and Tolerability of Warfarin in the First Year of Therapy Among Elderly Patients With Atrial Fibrillation // Circulation. 2007. №115. Р. 2689−2696.

56. URL:http://www.accessdata.fda.gov/scripts/ cder/drugsatfda/index.cfm?fuseaction=Search. Label_ApprovalHistory#labelinfo.

57. Ghate S.R., Biskupiak J.E., Ye X., et al. Hemorrhagic and Thrombotic Events Associated with Generic Substitution of Warfarin in Patients with Atrial Fibrillation: A Retrospective Analysis // Ann. Pharmacother. 2011. №45. Р. 701−712.

58. Mega J.L., Braunwald E., Mohanavelu S., et al., on behalf of the ATLAS ACS-TIMI 46 study group. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial // Lancet. 2009. №374. Р. 29–38.

59. APPRAISE Steering Committee and Investigators. Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome. Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) Trial // Circulation. 2009. №119. Р. 2877−2885.

60. Alexander J.H., Lopes R.D., James S., et al., for the APPRAISE-2 Investigators. Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome // N. Engl. J. Med. 2011. №365. Р. 699−708.

61. Komocsi A., Vorobcsuk A., Kehl D., Aradi D. Use of New-Generation Oral Anticoagulant Agents in Patients Receiving Antiplatelet Therapy After an Acute Coronary Syndrome. Systematic Review and Meta-analysis of Randomized Controlled Trials // Arch. Intern. Med. 2012. №172. Р. 1537−1545.

62. Oldgren J., Wallentin L., Alexander J.H., et al. New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis // Eur. Heart. J. 2013. doi:10.1093/eurheartj/ eht049.

63. Connolly S.J., Connolly S.J., Ezekowitz M.D., et al., for the RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation // N. Engl. J. Med. 2009. №361. Р. 1139−1351.

64. Patel M.R., Mahaffey K.W., Garg J., et al., for the ROCKET-AF Investigators. Rivaroxaban versus warfarin in nonvalvularatrial fibrillation // N. Engl. J. Med. 2011. №365. Р. 883−891.

65. Granger C.B., Alexander J.H., McMurray J.J., et al., for the ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation // N. Engl. J. Med. 2011. №365. Р. 981−992.

66. Dans A.L., Connolly S.J., Wallentin L., et al. Concomitant Use of Antiplatelet Therapy with Dabigatran or Warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Trial // Circulation. 2013. №127. Р. 634−640.


Для цитирования:


Явелов И.С. АНТИТРОМБОТИЧЕСКИЕ ПРЕПАРАТЫ В ПРОФИЛАКТИКЕ ТРОМБОТИЧЕСКИХ И ТРОМБОЭМБОЛИЧЕСКИХ ОСЛОЖНЕНИЙ ПОСЛЕ ОСТРОГО КОРОНАРНОГО СИНДРОМА. Атеротромбоз. 2013;(1):82-104. https://doi.org/10.21518/2307-1109-2013-1-82-104

For citation:


Явелов И.С. . Atherothrombosis. 2013;(1):82-104. (In Russ.) https://doi.org/10.21518/2307-1109-2013-1-82-104

Просмотров: 377


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2307-1109 (Print)
ISSN 2658-5952 (Online)